Clinical Trial Update: A Study of Adenovirus Serotype 26.Respiratory Syncytial Virus.Pre-Fusion F (Ad26.RSV.preF)-Based Vaccine for Prevention of Respiratory Syncytial Virus (RSV) Mediated- Lower Respiratory Tract Disease (LRTD) in Japanese Participants [Phase 3]

View source ↗

Summary

Phase 3 study of the Ad26.RSV.preF-based vaccine for prevention of RSV-mediated lower respiratory tract disease in Japanese participants has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lower Respiratory Tract Disease
• Respiratory Syncytial Virus Infection

Drugs mentioned

• Ad26.RSV.preF-based vaccine (Ad26.RSV.preF)

Snippet

Sponsor: Janssen Pharmaceutical K.K. | Conditions: Respiratory Syncytial Virus Prevention | Phase 3 | Status: TERMINATED